Intrizole Plus Cream is a topical formulation combining Ketoconazole (2% w/w), Clioquinol (Iodochlorhydroxyquin) (1% w/w), Tolnaftate (1% w/w), Neomycin (0.1% w/w), and Clobetasol (0.05% w/w) designed for the treatment of mixed fungal and bacterial skin infections accompanied by inflammation and pruritus. Ketoconazole, a broad-spectrum antifungal agent, inhibits ergosterol synthesis, disrupting fungal cell membranes. Clioquinol exhibits antimicrobial activity against fungi and certain bacteria, enhancing the antifungal spectrum. Tolnaftate provides additional antifungal efficacy, particularly against dermatophytes. Neomycin, an aminoglycoside antibiotic, targets susceptible bacterial pathogens, preventing secondary bacterial infections. Clobetasol, a potent corticosteroid, exerts anti-inflammatory, antipruritic, and vasoconstrictive effects, reducing erythema, swelling, and itching associated with dermatoses. Intrizole Plus Cream is indicated for dermatophytosis, candidiasis, and mixed infections where inflammation is prominent. The combination therapy ensures comprehensive management by addressing fungal and bacterial components while alleviating inflammatory symptoms. It should be applied topically as directed by a healthcare professional, avoiding prolonged use to minimize corticosteroid-related adverse effects such as skin atrophy or systemic absorption. Caution is advised in patients with hypersensitivity to any components. Intrizole Plus Cream offers an effective therapeutic option for complex superficial infections requiring multifaceted intervention.